and plasma cGMP levels. Details of these assays are presented, together with evidence for their validity.
cGMPt has become the subject of considerable interest during the last five years as an alternative 'second messenger' to cAMPt for the actions of some hormones. There is now evidence that cholinergic and IX-adrenergic stimulation and the actions of certain peptide hormones-such as cholecystokinin, histamine, and possibly insulin-are mediated by anincrease in the intracellular level of cGMP rather than of cAMP (Nature, 1973) . In some tissues, changes in the cAMP/cGMP ratio may determine the nature of the response to hormone stimulation (Goldberg et al., 1975) , and it should, therefore, be of interest to be able to monitor both cyclic nucleotides in tissues and extracellular fluids.
In mammalian tissues cGMP is present at approximately one-tenth to one-hundredth the concentration of cAMP. Human plasma and urine cGMP/cAMP ratios are approximately 1:2 and 1:10 respectively. Consequently, an assay system of high sensitivity as well as of high specificity is required to measure cGMP in the presence of cAMP and other nucleotides, Protein-binding assays for cGMP, which utilise intracellular receptor proteins from lobster tail muscle (Murad et al., 1971) , silkmoth pupae (Fallon and Wyatt, 1975) , or rat lung (Kobayashi and Fang, 1975) lack sensitivity and are not specific enough to be used for the analysis of tissue extracts without preliminary nucleotide fractionation.
The measurement of cG MP by radioimmunoassay (Steiner et al., 1972b) has the advantages of greater sensitivity and specificity over protein-binding • Present address: Department of Chemical Pathology Southampton General Hospital, Southampton tcGMP is used as the abbreviation for guanosine-3'S'-cyclic phosphate, cAMP as the abbreviation for adenosine-3'S'cyclic phosphate methods and for this reason it was decided to develop such an assay system.
Materials and methods
ANTISERUM PRODUCTION 2'-O-Succinyl cGMP (a gift from the Boehringer Corporation) was conjugated to ovalbumin (Sigma Fraction V) or to kehole limpet haemocyanin (Cal-Biochem) using the carbodiimide 'EDC' (l-ethyl-3 (3-dimethyl-amino-propyl)-earbodiimide Hel) in accordance with the method of Steiner et al. (1972b) . The conjugates were estimated by making spectroscopic measurements of solutions of the conjugates, unconjugated 2'-O-succinyl cGMP, and proteins, to contain six molecules of cGMP per molecule of ovalbumin or 160 molecules of cGMP per molecule of kehole limpet haemocyanin (average mol. wt. 3 x 10 6 Daltons). The conjugates were stored freezedried in aliquots containing 1 mg protein.
Five white half-lop rabbits (Ranch Rabbits Ltd) were each given a primary immunisation in six intramuscular sites with a total of 1 mg of the 2'-o-succinyl cG MP-ovalbumin conjugate per rabbit. The conjugate was dissolved in sterile water and emulsified in two volumes of 'Marcol 52' adjuvant (Marks et al., 1974) containing Bacillus Calmette Guerin (BCG; 3 mg/rng conjugate). The rabbits were given seven boosts at monthly intervals using the same regimen, but with the omission of BCG from the adjuvant. Blood samples were taken from an «:a:r vein 10 days after each boost. Because serum antibody titres remained very low on this regimen, the 2'-O-succinyl cGMP-kehole limpet haemocyanin conjugate, suspended in the same adjuv:ant system as before, was then used to boost the rabbits (0'25 mg protein per rabbit given as six intramuscular 25 Mix, leave at 4°C for 10 min, centrifuge for 30 min at 1800 g (Mistral4L Centrifuge). Aspirate supernatants and redissolve precipitates in 1'0 ml distilled water. Mix and take 0'5 ml aliquots for liquid scintillation counting.
Scatchard plots of the data from five standard curves using antiserum T5 were linear, and were interpreted in terms of a single antibody population with a mean dissociation constant Kn = 3·1 x 10-9 rnol/l. A similar treatment of the data from two standard curves using antiserum T2 yielded curved Scatchard plots which could be interpretcrf-in terms Assay buffer (Tris 50 mrnoljl, 100 100 300 pH "5, containing disodium EDTA,4 mmol/I) Test urine (Diluted 1 in 20 100 in assay buffer) Standards (0-10 pmol cGMP 100 per 100 /"1 in assay buffer) (8·'HlcGMP (Amersham TRK 392; 1 pmol/50 50 50 50 /"1 in assay buffer) Antiserum (T2 or T5; working 100 100 dilution 1 in SO in assay buffer) Mix, incubate for 3 hours at 4 "C, then add: Bovine y globulin 10 10 10 (Sigma fraction II; 10 mg/ml assay buffer) (NH.),SO. Solution 1'0 ml 1·0 ml 1'0 ml (lee-cold; 3'8 mol/I)
Tests
Standards Non-specific hinding (NSB) Additions (/"I) injections). After the second monthly boost with this conjugate, antibody titres rose to between 1 in 50 to 1 in 100 (working dilution). Antisera from two of the rabbits, T2 and T5, proved highly specific for cGMP. These were diluted 1 in 5 with buffer (50 mmol/l Tris, pH 7'5, containing theophylline 8 rnmol/l and 2-mercaptoethanol 6 mmolfl) and stored freeze-dried in small aliquots.
CHARACTERISATION OF ANTISERA T2 AND
T5
The influence of pH on the binding of 3H cGMP was studied over the pH range 3'5 to 9·0 using 50 mmol/l acetate, phosphate, or Tris buffers containing theophylline (8 rnmol/l) and 2-mercapto ethanol (6 mmol/l), The two antisera differed in their ability to bind the label at different pHs. Antiserum T2 showed a steady level of binding over the pH range 4'5 to 9,0, while antiserum T5 showed increased binding at pH 4·5. Further studies on the properties of both antisera were carried out at pH 7'5, using the assay protocol described below for the analysis of urine (Table 1) . The length of incubation had little effect on the standard curve for either antiserum. Incubations of 5, 30, 60, 90, or 180 minutes yielded very similar standard curves, and the 5-minute and 3-hour incubation standard curves were not significantly different when compared by a paired Student's t test on the standard points. Test results for incubations of less than 30 minutes were unreliable, however. An incubation time of three hours was routinely used for the analysis of test samples. Cross-reactivity of 17 nucleotides with antiserum T5 determined using the incubation procedure described in Table I . cGMP levels in plasma from 18 normal subjects, collected with or without disodium EDTA. EDTA-plasma was stored at -20°C, while 'blank' samples were left at room temperature overnight (for details see the text). of two antibody populations with mean dissociation constants Kni = 1·0 x 10-9 mol/l and KD2 = 1·8 X 10-8 mol/I. Figure 1 illustrates the crossreactivities of 17 nucleotides in the assay system using antiserum T5. Similar results were obtained with T2 (not shown). In particular cAMP was 10000 times less potent in displacing the [3H} cGMP label from the antiserum than was cGMP. cGMP assay protocol-urine analysis Details of the assay protocol for the analysis of urine and protein free tissue extracts are shown in Table 1 . The addition of 10 ,ul of a solution of bovine ')I-globulin (Sigma Fraction II; 10 rng/ml) as a 'carrier' protein, before the precipitation of bound radioactivity with ammonium sulphate increased the precision of results for duplicate analyses. Half-millilitre aliquots from the dissolved precipitates were transferred to 'minivials' (G.D. Searle and Co.), mixed with 4·0 ml of toluene-'Synperonic-NXP' scintillant (Wood et al., 1975) , and the tritium content measured on an LKB 'Ultrabeta 1210' liquid scintillation counter with an efficiency of 35 %.
Initially a Tris-mercaptoethanol buffer containing theophylline, a less potent inhibitor of cyclic nucleotide phosphodiesterase than EDTA, was used as the assay buffer. Standard curves for incubations with the two buffer systems were identical, and no change in the cG MP levels measured in four urine quality control pools was observed as a result of the change to the Tris/EDTA buffer.
There was no evidence of rapid degradation of cGMP, and samples showed no loss of cGMP content after being left at either room temperature or at 4°C for periods of up to five days. Nevertheless, quality controls and urine specimens for clinical investigation were stored at -20°C before analysis.
VALIDATION OF THE URINE ASSAY
Recovery lof cGMP (2 ,umol/l) added to urine samples from 10 normal subjects was 95·2 ± 2·6~( mean ± s.e.m.) and 94·1 ± 2·1 % with antisera T5 and T2 respectively. The analysis of a high test urine gave results which were independent of the urine dilution, provided the individual assay values fell within the range 0'1-10 pmol cGMP per tube.
Detection limits calculated by the method of Ekins (1974) for assays using either antiserum T2 or T5, were both in the region of 0'08 pmol cGMP per tube. Treatment of urine samples from 11 normal subjects with ox-heart phosphodiesterase reduced the measured cG MP levels to below the detection limit in every case (Fig. 2, top) .
A comparison of the results of analyses for cG MP in urine obtained using two radioimmunoassays employing antiserum T2 and antiserum T5, and a specific locust protein binding assay (Wood et al., 1976) showed close agreement between all three methods ( Table 2) .
Interassay coefficients of variation for radioimmunoassay using either antiserum T2 or T5 varied between 4·2 %and 8'7 %for test levels in the range 0·9 to 8'7 pmol cGMP per tube. Ammonium sulphate precipitation of the bound counts created problems when plasma or other types of sample with a high protein content were analysed. Considerable amounts of the reagent were trapped in the bulky protein pellet and the addition of an aliquot of the resuspended pellet to the scintillation medium produced a dense white precipitate. To overcome these difficulties a direct plasma radioimmunoassay, using second antibody separation of bound counts, was developed. The protocol for this method is set out in Table 3 . Incubate overnight at 4 "C. Centrifuge, aspirate supernatants, resuspend precipitates in 0·6 ml saline (9 g/I). mix. Remove 0·5 ml aliquot for liquid scintillation counting (as for the urine assay). blood which, because of age, was no longer suitable for transfusion, and stirred with Norit A charcoal (20 g/loo ml plasma) for 24 hours at 4°C. The mixture was centrifuged and the supernatant plasma vacuum filtered through a Seitz bacteriological filter. The clear plasma was mixed with 0·5 mol/l EDTA (pH 7'5) to give a final EDTA concentration of 5 mmol/l plasma, and small aliquots were stored at -20°C until required.
Blood samples for cGMP analysis were collected into lithium heparin tubes (10 iu lithium heparin/rnl blood) containing 1 % of the blood volume of 0'5 mol/I EDTA (pH 7'5) to prevent cyclic nucleotide degradation by endogenous cyclic nucleotide phosphodiesterase enzyme. Plasma was quickly separated and stored at -20°C.
VALIDATION OF THE PLASMA ASSAY
To test the specificity of the assay, blood samples were taken from 18 normal subjects and each specimen was divided into two. Half was added to a lithium heparin tube containing EDTA, the plasma was separated and stored frozen; the other half was taken into heparin alone, and the plasma, after separation, was left overnight at room temperature. In each case the endogenous phosphodiesterase present in the samples left overnight at room temperature reduced cGMP levels to below the detection limit of the method, calculated to be 0'05 pmol per tube or 0'25 pmol per ml of plasma (Fig. 2, bottom) .
Recovery of cGMP (6 pmol/tube) added to 18 plasma samples was 98·1 ± 2'0% (mean ± s.e.m.).
The method as described was also satisfactory with regard to parallelism of the results with the standard curve when high test plasmas were analysed at different dilutions in stripped plasma. Five plasma samples were extracted with ethanol, the extracts were dried, and the residues taken up in assay buffer according to the method of Brown et al. (1971) . These extracts were then analysed for cGMP by radioimmunoassay, using standards made up in a similar extract of stripped plasma. There was good agreement between results obtained after ethanol extraction and by direct plasma assay (Table 4 ). Concentrations of cAMP and cGMP found in the samespecimens of urine and of plasma from normal subjects are shown in Table 5 . Urinary cAMP concentrations were determined by the method of Brown et al. (1971) , plasma cAMP content was measured using the method of Tovey et al. (1974) (Amersham kits; TRK 432), and cGMP by the methods described above.
succinyl group, to protein before immunisation. Succinyl-cyclic-GMP was 10 times more potent in displacing labelled cGMP from antibody binding than was cGMP itself. There is, therefore, the potential to develop assays of even greater sensitivity than those described here by the introduction of initial succinylation for test samples. The values for normal urine and plasma cG MP levels obtained with the present method agree well with published data (Murad and Pak, 1972; Steiner et al., 1972a; Lebeau et al., 1975; Neethling and Shanley, 1976; Rosman et al., 1976; Rudman et al., 1976; Siddle et al., 1976) .
The high specificity of the antisera towards cGMP alone among naturally occurring compounds permits direct analysis of urine and plasma samples. This is in contrast to all previous methods for measuring plasma cGMP, which have required preliminary extraction of test samples. It may also prove possible to analyse tissue homogenates for cGMP without preliminary nucleotide fractionation, but this has still not been tested.
The results indicate that there is little need to analyse individual 'blank' plasma samples, collected in the absence of a phosphodiesterase inhibitor, at least for normal subjects. It will be necessary in the future to establish whether there is a need to do so for pathological samples. 
, Discussion
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The factors which influence the production of specific, high titre antisera are still poorly understood. There is some evidence from this study that 2'-o-succinyl cG MP conjugated to kehole limpet haemocyanin, itself a highly immunogenic protein, may have elicited a better immune response to the hapten cGMP than did the ovalbumin conjugate.
Both the antisera, T2 and T5, chosen for investigation for their potential use in radioimmunoassay were found to be remarkably specific for cGMP. Of the four other cyclic nucleotides, cIMP cross-reacted , to the greatest extent. This is probably of little \ practical importance. Steiner et al. (1970) were I unable, using a specific radioimmunoassay, to , detect cIMP in tissue samples. cUMP and cCMP I have, however, recently been isolated from rat liver and other tissues (Bloch, 1975a,b) . Synthetic butyrated cyclic nucleotides cross-reacted to a measurable degree in the assay procedure. This was . not altogether surprising, since one of the positions , of substitution of the butyryl group is the 2' position on the ribose ring, which is the point on the , cGMP molecule through which it was linked, via a
